 | A major contributor to this article appears to have a close connection with its subject. (June 2021) |
 | |
 Wockhardt global headquarters in Mumbai | |
| Company type | Public |
|---|---|
| NSE: WOCKPHARMA BSE: 532300 | |
| Industry | Pharmaceuticals Health care |
| Founded | 1960s |
| Founder | Habil Khorakiwala |
| Headquarters | Wockhardt Towers, Bandra Kurla Complex, Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people | Habil Khorakiwala (Chairman) Murtaza Khorakiwala (Managing director) Huzaifa Khorakiwala (Executive Director) |
| Products | Formulations Biopharmaceuticals Vaccines |
| Revenue |  ₹2,693 crore (US$320 million) (FY23)[1] |
 ₹−621 crore (US$−74 million) (FY23)[1] | |
Number of employees | 3,000 (2023) |
| Subsidiaries | Morton Grove Pharma[2] |
| Website | www |
| Footnotes / references [3] | |
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).[4] The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.[5][6]
- ^ a b "Wockhardt posts net loss of Rs 237 crore in Q4 FY 23". The Economic Times. 27 May 2023. Retrieved 2 March 2024.
- ^ "Wockhardt acquires US-based Morton Grove". The Economic Times. 24 October 2007. Retrieved 16 February 2023.
- ^ "Audited Financial Results For The Quarter And Year Ended 31.03.2021" (PDF). BSE. Retrieved 27 May 2021.
- ^ "Wockhardt – Who we are".
- ^ Cite error: The named reference
birlaawas invoked but never defined (see the help page). - ^ "Wockhardt set to join billion-dollar club". Business Standard India. Business Standard. 20 March 2013. Retrieved 20 March 2013.